Subtitle
Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer
Subtitle
Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer
Proto therapy Time
February 2018
Executive summary
A multi-center prospective phase 3 randomized trial aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and extreme hypofractionated radiation. This report analyzed the results of the first 75 patients, comparing 38 Gy relative biologic effectiveness (RBE) in 5 fractions (n = 46) versus 79.2 Gy RBE in 44 fractions (n = 29).
With the median follow-up was 36 months, the study reported low AE rates in both study arms, and early temporary differences in genitourinary scores disappeared over time. The study also found no differences in the EPIC domains of bowel symptoms, sexual symptoms, or bowel ≥G2 toxicities.
Key content topics
Top cancer treatments
Related contents
Webinar
18 October 2024
Empowering Cancer Care with Proton Therapy
Rakesh
Jalali
Srinivas
Chilukuri
Daniela
Alterio
Proton Therapy Publication
July 2024
Quantifying dose uncertainties resulting from cardiorespiratory motion in intensity-modulated proton therapy for cardiac stereotactic body radiotherapy.
Proton Therapy Publication
July 2024
Initial experience and patient tolerance of proton stereotactic body radiotherapy.
Proton Therapy Publication
March 2024
A multicenter high-quality data registry for advanced proton therapy approaches: the POWER registry.
Webinar
March 29, 2023
Hypofractionation in Proton Therapy: radiobiological bases and clinical applications
Roberto
Orecchia
Barbara
Jereczek
Daniela
Alterio
Dante
Amelio
Jiri
Kubes
Proton Therapy Publication
March 2023
A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.
Proton Therapy Publication
November 2022
Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis.
Proton Therapy Publication
May 2022
The Role of Hypofractionation in Proton Therapy.
Proton Therapy Publication
April 2022
Outcome after Radiotherapy for Vestibular Schwannomas – Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy.